Grade of Cancer — Cellular Differentiation and Growth Rate

Tumour grading is conducted by an anatomical pathologist who examines stained biopsy or resection specimens. The assessment focuses on cellular morphology, tissue architecture, nuclear atypia, and mitotic rate (the frequency of actively dividing cells). Well-differentiated tumours retain recognisable architectural features of the original healthy tissue, whereas poorly differentiated or undifferentiated tumours lose these structures and exhibit chaotic, disorderly cellular growth.

Grading systems vary according to tumour histology. Most solid malignancies are categorised from Grade 1 to Grade 3 or 4. Grade 1 (low grade) denotes well-differentiated cells that typically divide slowly. Grade 2 (intermediate grade) represents moderately differentiated cells. Grade 3 and Grade 4 (high grade) describe poorly differentiated or anaplastic cells that divide rapidly and exhibit aggressive biological behaviour.

Cancer grade plays an essential role in clinical decision-making and prognosis. Together with tumour stage (the anatomical extent and spread of disease) and molecular biomarkers, grade helps oncologists predict how quickly a cancer might progress. A low-grade tumour may allow for conservative, organ-sparing management or active surveillance. In contrast, a high-grade tumour often demands more prompt, aggressive systemic therapies, such as adjuvant chemotherapy or intensive radiotherapy, even when the tumour appears small or localised.

Cancer grade is determined through microscopic examination of formalin-fixed, paraffin-embedded tissue obtained via core biopsy or surgical resection. Pathologists use routine haematoxylin and eosin (H&E) staining alongside immunohistochemical stains. Mitotic figures are counted, and specific proliferation biomarkers, such as Ki-67 labelling index, are frequently measured to assess the proportion of actively replicating cells, confirming the morphological grade.

Grading applies to almost all solid malignancies, soft tissue tumours, and primary brain tumours. It is particularly prominent in breast cancer (Nottingham histologic grade), prostate cancer (Gleason grading), soft tissue sarcomas (FNCLCC system), endometrial carcinomas, renal cell carcinomas, bladder urothelial carcinomas, and central nervous system tumours such as astrocytomas and glioblastomas graded under World Health Organization (WHO) criteria.

Tumour grade substantially dictates systemic and local therapy planning. High-grade cancers frequently prompt the addition of adjuvant chemotherapy, targeted regimens, or broader radiotherapy fields because of their higher risk of microscopic recurrence and metastasis. Conversely, low-grade malignancies may be managed effectively with surgical resection alone, endocrine therapy, or active observation, sparing patients unnecessary treatment-related toxicities when aggressive intervention provides no added survival benefit.